A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...
SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...
Proceeds to support registration-enabling trials, DOMMINO-1 and DOMMINO-2, and continued development of the first-in-class p300/CBP inhibitor Financing led by Venrock Healthcare Capital Partners, with ...
Hosted on MSN
Living longer and stronger with multiple myeloma
Why it matters: Multiple myeloma is the second most common blood cancer in adults, affecting over 127,000 Americans, with survival rates steadily improving due to treatment advances. What’s changing: ...
A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...
The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseqTM, a ...
Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...
A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...
How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...
Physical Activity Improves Performance, Frailty Scores, PROs in Multiple Myeloma Bispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, ...
While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...
Intensive Therapy More Effective vs Less Intense Therapy in Frail Patients With MM BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results